Clinical Trial Update: Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating the efficacy and safety of muscarinic M3 receptor antagonists for neurogenic detrusor overactivity in individuals with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity
• Spinal Cord Injury

Snippet

Sponsor: Toronto Rehabilitation Institute | Conditions: Spinal Cord Injury, Neurogenic Detrusor Overactivity | Phase 4 | Status: COMPLETED